Skip to main content

Advertisement

Table 4 Oxaliplatin and fluoropyrimidine as second-line chemotherapy in advanced pancreatic cancer

From: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

Authors Prospectives Studies No. of Patients First-line therapy Regimen ECOG Performance status (PS) ORR Median TTP Median OS Main Toxicities grade 3-4
Androulakis N et al., 2005 [18] Phase II 18 Gemcitabine-based, n=18 oxali 180 mg/m2 q3weeks PS 0, n=4 PS 1, n=9 PS 2, n=5 0% _ 3.5 mo Diarrhoea 5% Vomiting 5% (Neutropenia 0%)
Tsavaris N et al., 2005 [23] Phase II 30 Gemcitabine, n=30 oxali 50 mg/m2 D1,Leucovorin 50 mg/m2 D1,5FU 500 mg/m2 D1,q1 week KPS 100-80%, n=10 KPS 70-50%, n=20 23% 22 wks 25 wks Leucopenia 16% Diarrhoea 14%
Mitry E et al., 2005 [19] phase II 18 Oxaliplatin, n=10 5FU, n=8 oxaliplatin 130 mg/m2 D1,5FU 1000 mg/m2 D1-D4,q3weeks PS 0-1, n=4PS 2, n=7 PS > 2, n=4 Unknown, n=3 0% 0.9 m 1.3 mo Neutropenia 19% Anemia 25% Asthenia 56%
Xiong HQ et al., 2008 [20] Phase II 41 _ oxaliplatin 110–130 mg/m2 D1,capecitabine 1.5-2 g/m2 D1-D14q3week PS 0, n=4 PS 1, n=16 PS 2, n=8 3% 9.9 wks* 23 wks Asthenia 13% Diarrhoea 5%
Pelzer U et al., 2009 [21] Phase II 37 Gemcitabine, n=37 oxaliplatin 85 mg/m2 D8, 22 folinic acid 500 mg/m2 D1,8,15,225FU 2600 mg/m2 D1,8,15,22 q6weeks KPS 90-60%, n=37 6% 12 wks 22 wks Nausea/vomiting 11% Diarrhoea 12%
Novarino A et al., 2009 [22] Phase II 23 Gem alone, n=13 Gem/5FU/cisplatin, n=5 Gem/5FU, n=4 Gem/oxaliplatin, n=1 oxaliplatin 40 mg/m2 D1,8,15 leucovorin 250 mg/m2 D1,8,15 5FU 500 mg/m2 D1,D8,15 q4weeks PS 0, n=6 PS 1, n=11 PS 2, n=6 0% 11.6 wks 17.1 wks Diarrhoea 9% (Neutropenia 0%)
Yoo C et al., 2009 [14] Randomised phase II (versus FOLFIRI3) 30 Gem alone, n=2Gem/cap, n=26 Gem/erlotinib, n=2 oxaliplatin 85 mg/m2 D1 leucovorin 400 mg/m2 D1 5FU 2000 mg/m2 D1,D2 q2weeks PS 0, n=5 PS 1, n=24 PS 2, n=1 7% 6 wks* 14.9 wks Neutropenia 20% Asthenia 14%
Pelzer U et al., 2011 [8] Randomised phase III (versus BSC) 23 Gemcitabine, n=23 oxaliplatin 85 mg/m2 D8, 22 folinic acid 200 mg/m2 D1,8,15,22 5FU 2000 mg/m2 D1,8,15,22 q6weeks KPS 100-90%, n=12 KPS 80-70%, n=11 _ _ 4.82 mo (vs 2.3 mo BSC) Diarrhoea 9% (Neutropenia 0%)
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, KPS Karnofsky Performance status, BSC Best Supportive Care, TTP Time To Progression, PFS Progression Free Survival, OS Overall Survival.
  2. *Evaluation according to PFS.